Allelic alterations of chromosomes 1 and 19 are frequent events in human diuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross et al., 1998; Smith et al., submitted). Using 115 human diuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH),¯uorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). The correlation coecients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH. Minimal deletion regions were de®ned on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612). Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P50.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P=0.0017). Loss of both regions was found in 11% (6/55) of astrocytomas and in 64% (21/33) of oligodendrogliomas (P50.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.
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Diuse gliomas are the most common primary central nervous system tumor aecting adults, with nearly 15 000 diagnosed annually in the United States and a mortality approaching 80% in the ®rst year after diagnosis (Levin et al., 1993) . Despite this poor prognosis, our understanding of diuse glioma development and progression remains modest, and our abilities to eectively stratify and treat these malignancies continues to be limited.
Diuse gliomas are comprised of a heterogeneous collection of histological subtypes, including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas (MOAs). While these tumors are often grouped together, dierences in clinical behavior and response to therapy warrant separation. However, distinguishing pure oligodendrogliomas and mixed oligoastrocytomas from astrocytomas based on histology alone is subject to considerable interobserver variability. We have been interested in de®ning potential molecular markers to facilitate the classification of diuse gliomas and to aid in further stratifying these tumors into various genetic subtypes. Such markers may provide important clues to the histogenesis of these gliomas, as well as potentially aid in therapeutic decisions.
The importance of distinguishing among the diuse glioma histological subtypes and further stratifying within each subtype is exempli®ed by the often remarkable chemosensitivity of a subset of anaplastic oligodendrogliomas, with as many as two-thirds responding to chemotherapeutic treatment (Cairncross and Macdonald, 1988; Glass et al., 1992; Cairncross et al., 1994; Kim et al., 1996; Mason et al., 1996) . In a recent retrospective analysis, Cairncross et al. (1998) used a set of 39 anaplastic oligodendrogliomas to demonstrate that allelic loss of the chromosome 1 p-arm is a strong predictor of chemotherapeutic response. They further demonstrated in the same set of anaplastic oligodendrogliomas that combined loss of chromosome arms 1p and 19q is associated with both chemotherapeutic response and prolonged recurrence-free survival post-chemotherapy. Additionally, our group has recently shown that these combined alterations are predictive of prolonged survival in a predominantly low-grade (WHO II) collection of oligodendrogliomas (Smith et al., submitted) . Identifying the spectrum of these alterations in the diuse glioma subtypes and mapping the A IV  A IV   A IV  GS IV   A IV  A IV   A IV  M IV  O-5  O-7  62  70  71  77  87  94  95  99  102  O-107  O-109  113  136  137  O-138  O-142  143  149  156   M II  M IV  O II  A IV  A IV  O II  A IV  A IV  A IV  M III  A IV  M II  M II  A IV  A IV  A IV  O II  O II  A IV  A IV  A IV   O III  M IV  O II  A IV  A IV  O II  A IV  A IV  A IV  M III  A IV  M II  O III  A IV  A IV  A IV  O II  O II  A IV  A IV  A IV   M II  M IV  O II  A IV  A IV  O II  A IV  A IV  A IV  A III  A IV  M II  M II  A IV  A IV  A IV  O II  M II  A IV  A IV  A IV   M II  O IV  O II  A IV  A IV  O II  A IV  A IV  A IV  O II  A IV  O II  A II  A IV  A IV  A IV  O II  O II  A IV  A IV  A IV   427  467  482  502  537  554  555  580  584  588  611  1750  1775  1779  1892  1906  1913  2051  2114  2167  2235   O III  O II  A IV  O II  A IV  A IV  O II  M III  M III  O III  O III  A IV  A IV  A III  A IV  A IV  A IV  A IV  A IV  A III  A IV   O III  O 
This set consists of 115 surgically resected diuse gliomas obtained from the Mayo Clinic in Rochester, MN (83 cases), Johns Hopkins Hospital in Baltimore, MD (21 cases), and the University of California at San Francisco (11 cases). These tumors were classi®ed morphologically and scored according to World Health Organization (WHO) guidelines (Kleihues et al., 1992) by three independent neuropathologists (BW Scheithauer, PC Burger, and A Yates). Consensus morphology and grade were established for each glioma, de®ned as the morphology and grade as agreed upon by at least two of the three neuropathologists. Cases that lacked histologic subtype agreement of at least two neuropathologists, but for which astrocytic and oligodendroglial features were observed, were classi®ed as mixed oligoastrocytomas (cases 99, O-109, O-235, 250, 407, and 584) . Consensus grade was established by averaging the grades for cases that lacked agreement of at least two neuropathologists (cases O-76 and O-250) . Tumors from an initial surgical resection were classi®ed as primary, and tumors from a non-initial surgical resection were classi®ed as recurrent. Abbreviations include: A=astrocytoma, O=oligodendroglioma, M=mixed oligoastrocytoma, GS=gliosarcoma, PX=pleomorphic xanthoastrocytoma, and UNC=unclassi®able. LOH of D19S412 (19q13. 3) relative to control marker D2S126 in DNA extracted from tumor tissue (T) as compared to DNA extracted from corresponding patient lymphocytes (L). LOH, FISH, and CGH were performed as previously described (Cliby et al., 1993; Ritland et al., 1995; Qian et al., 1995; Mohapatra et al., 1995 Mohapatra et al., , 1998 Piper et al., 1995) . Selected microsatellite markers were placed in their most probable linkage order based upon radiation hybrid and physical mapping (GDB Human Genome Database, 1990; Collins et al., 1992; Murray et al., 1994; Ashworth et al., 1995) . Allelic dosage for LOH analyses was determined by visual inspection and by multiplex PCR using a control primer set to normalize for DNA loading. Allelic intensities for multiplex PCR were quanti®ed using Molecular Dynamics Phosphoimaging screens, the Molecular Dynamics 445SI scanner, and ImageQuaNT v3.2 software (Molecular Dynamics, Sunnyvale, CA, USA). Five bacterial arti®cial chromosomes (BACs) were labeled to generate locus-speci®c FISH probes (LSFP) mapping to 1p36, 1q24, 19p13.1, 19q13.1 ± q13.2, and 19q13.3 . The BAC mapping to 19q13.3 was selected based on previous reports that this band contains a region of common allelic loss in gliomas (Rosenberg et al., 1996; Smith and Jenkins, 1997) . The BAC mapping to 19q13.1 ± q13.2 was selected using primers for the AKT2 oncogene (Genome Systems, St. Louis, MO, USA). The values in the FISH tables summarize the per cent nuclei with the indicated number of 1p36 and 1q24 or 19p13 and 19q13.3 signals putative tumor suppressor regions on 1p and 19q are important steps to further understand the signi®cance of these alterations and to eectively translate this tool to the clinical setting.
Numerous genetic alterations have been de®ned in human gliomas (Ransom et al., 1992; Bello et al., 1994 Bello et al., , 1995 Reifenberger et al., 1994; Kraus et al., 1995; Mohapatra et al., 1995 Mohapatra et al., , 1998 Louis and Gusella, 1995; Weber et al., 1996; Louis, 1997) . Brie¯y, tumors of astrocytic lineage often demonstrate alterations of chromosome arms 7p, 7q, 9p, 10p, 10q, 11p, 13q, 17p, 19q and 22q, while oligodendrogliomas and MOAs commonly have loss of 1p and 19q. Notably, loss of one copy of 17p and mutation of the remaining p53 allele occurs in approximately 30 ± 40% of highgrade (WHO III and IV) astrocytomas (Chung et al., 1991; Fults et al., 1992; Frankel et al., 1992) , while rarely occurring in pure oligodendrogliomas (Reifenberger et al., 1994) .
In this study of 115 diuse gliomas, we ®rst established the consensus histological subtype of each tumor and screened for alterations of chromosomes 1 and 19 using microsatellite analysis (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). Second, we evaluated boundaries of common allelic loss for chromosome arms 1p, 19p and 19q in hopes of narrowing the search for potential tumor suppressor genes. Third, we examined the spectrum of alterations encountered in each glioma subtype and evaluated the association of 1p and 19q deletions with histological subtypes for potential application as diagnostic and prognostic markers. Lastly, we assessed the concordance and correlation among LOH, FISH, and CGH for detection of these alterations. Table 1 lists the histological subtype and grade for each glioma used in this study as determined by each pathologist (A, B and C), as well as the consensus diagnosis and the primary/recurrent status. For 80 of 115 cases (70%), histological subtype was agreed upon by all three pathologists. The kappa statistics (Cohen, 1960) for the correlations between pathologists A and B, A and C, and B and C for histological subtype classi®cation were 0.67, 0.61 and 0.66, respectively. Based on consensus morphology and grade, the collection of tumors in this study included: 66 astrocytomas (two grade II, six grade III, 58 grade IV), 33 oligodendrogliomas (23 grade II, eight grade III, two grade IV) and 16 MOAs (six grade II, seven grade III, three grade IV).
Representative histology, CGH pro®les, LOH autoradiographs, and FISH images for oligodendroglioma O-197 are shown in Figure 1 . The CGH pro®les for chromosomes 1 and 19 for this case clearly demonstrate loss of 1p and 19q, and microsatellite analysis of D1S1612 and D19S412, mapping to 1p and 19q, respectively, also show allelic loss. In addition, the FISH images for the same tumor show hemizygous deletion of both the 1p36 and the 19q13.3 probes. Diagrammatic representation of data collected from all three molecular techniques, LOH, CGH, and FISH, is presented in Figure 2 . Tumors are divided by consensus glioma histological subtype and are further divided by 19q genetic alteration.
Based on the frequency of genetic alterations encountered on 1p and 19q in diuse gliomas, it is likely these chromosome arms harbor genes important for glioma development. Alterations of the chromosome 19 q-arm are of particular interest, because they are the only known alterations shared by all three glioma subtypes (Reifenberger et al., 1994; Kraus et al., 1995) . Further, most other common malignancies rarely demonstrate loss of 19q , suggesting the presence of a glial-speci®c tumor suppressor gene on this chromosome arm. In the present study, we de®ned a 1.5 megabase region of overlapping allelic loss on 19q between the genetic markers D19S412 and D19S596 using LOH and FISH data from 11 tumors (seven grade IV astrocytomas: cases 102, 113, 126, 162, 285, 298 and 554; one grade II astrocytoma: case O-94; two grade II oligodendrogliomas: cases 100 and 240; and one grade IV mixed oligoastrocytoma: case 250). Eight of these gliomas retained allelic balance at D19S412 and had hemizygous deletion distal to D19S412, while three of these tumors maintained balance at D19S596 and demonstrated loss proximal to D19S596. All 55 gliomas that demonstrated allelic loss on 19q had deletion of this interval. This deletion region overlaps the one megabase interval (D19S412 to STD) previously reported (Rosenberg et al., 1996) . However, all eight cases used in the Rosenberg study to de®ne the region of common allelic deletion were either grade III or grade IV astrocytomas, suggesting the potential importance of this region in the development of highgrade gliomas of astrocytic phenotype. The subset of gliomas in the present study with breakpoints in the 1.5 megabase region between D19S412 and D19S596 consisted of a variety of glioma subtypes and grades, suggesting that lesions of this region may be involved not only in the development of high-grade astrocytomas but also in the development of other gliomas, including low-grade astrocytomas, oligodendrogliomas, and high-grade mixed oligoastrocytomas.
Evidence of nonrandom loss of genetic material from chromosome 1 has been identi®ed in a broad range of tumors, from nearly all types of solid tumors to leukemias and myeloproliferative disorders (reviewed in Schwab et al., 1996) , suggesting a fundamental role of chromosome 1 alterations in the development of human cancer. We de®ned a region of common allelic loss on 1p36 between the genetic markers D1S1612 and D1S468. Two gliomas, one grade IV astrocytoma (case 255) and one grade II oligodendroglioma (case 278) maintained allelic balance at D1S468 and evidenced loss proximal to this marker. One grade II astrocytoma (case 375) maintained balance at D1S1612 and had allelic loss at the adjacent, telomeric marker D1S468. Three other gliomas, two MOAs (cases O-7 and 252) and one grade IV astrocytoma (case 228), maintained allelic balance at D1S1597, while exhibiting loss telomeric to this marker. All 40 gliomas with any evidence of imbalance on 1p included the D1S1612 to D1S468 region in the deletion. Bello et al. (1994) placed the region of common loss on 1p in human gliomas in the interval spanning 1p32 ± p36. The present study narrows this region of common allelic loss to a segment within 1p36. Despite the relative paucity of 1p alterations in astrocytomas, the majority of informative cases used to identify the 1p breakpoint were high-grade astrocytomas, since oligodendroglio- A red`R' denotes a recurrent lesion; remaining cases are primary lesions. Squares represent LOH data points and are color coded. Red squares represent multiplex-con®rmed allelic loss, and pink squares represent allelic imbalance that is inferred to be loss based on multiplex-con®rmed loss of other alleles on the same chromosome arm. Similarly, dark green squares represent multiplex-con®rmed allelic overrepresentation, while light green squares represent allelic imbalance inferred to be overrepresentation based on multiplex analysis of surrounding markers. Colorcoded circles depict FISH data, with blue representing no apparent alteration, red corresponding to hemizygous deletion, and green corresponding to overrepresentation. All green FISH data points re¯ect four copies of the probe, except for cases 336 and 2235 for which green FISH data points correspond to three probe copies. CGH data presented is that of chromosomes 1 and 19 only mas with alteration of 1p often lose the entire chromosome arm. Other investigators have also relied on high-grade astrocytomas to delineate 1p regions of overlapping deletion (Bello et al., 1994) .
The region of overlapping deletion de®ned in this study on 19p may delineate a putative tumor suppressor locus. Six gliomas suggested a region of common allelic loss on 19p13.1 ± 13.2 between the genetic markers D19S226 and D19S816. Three grade II oligodendrogliomas (cases 89, 231 and 502) and 2 grade IV MOAs (cases O-7 and 508) maintained allelic balance at D19S226 and exhibited loss telomeric to D19S226. One grade II oligodendroglioma (case 259) and one grade IV MOA (case O-7) retained balance at D19S816 and had loss centromeric to this marker. Deletions and rearrangements of this region have been identi®ed in a broad range of neoplasias, including acute lymphoblastic leukemias, lung carcinoma, cervical carcinoma, and familial breast carcinoma (Saltman et al., 1990; Baer, 1993; Lindbloom et al., 1993; Testa et al., 1994; Mullokandov et al., 1996) .
The spectrum of chromosome 1 and chromosome 19 alterations diered among the histological subtypes. Based on LOH and FISH data, the consensus oligodendrogliomas demonstrated a relatively homogeneous picture of genetic alterations of chromosomes 1 and 19 (Figure 2a) , with 64% (21/ 33) exhibiting loss of both the common 1p36 and 19q13.3 regions. Five of these 21 also had loss on 19p (cases 231, 259, 278, 427 and 502) , and four had also lost the 1 q-arm (cases 77, O-246, 535 and 611). Three oligodendrogliomas had a limited region of loss on 19q without apparent alteration of chromosome 1 (cases 100, 240 and 300), and two cases evidenced loss on 1p without apparent alteration of 19q (cases 89 and 588). Of the oligodendrogliomas with loss of the common 19q13.3 region, 88% (21/24) evidenced loss of the entire 19 q-arm. Interestingly, only one oligodendroglioma (case 587, +19q) had evidence of overrepresentation of either chromosome 1 or 19 genetic material by FISH or LOH. No alterations of either chromosome 1 or 19 were detected in six oligodendrogliomas (18%).
Based on LOH and FISH data, the genetic alterations of the astrocytomas (Figure 2b) were P-values re¯ect comparisons between astrocytomas (excluding mixed oligoastrocytomas) and were calculated using Pearson's and Fisher's exact tests. No signi®cant associations were found with regard to loss of the 1p36 region, loss of the 19q13.3 region, or loss of both the 1p36 and the 19q13.3 regions in primary astrocytomas versus recurrent astrocytomas or in primary oligodendrogliomas versus recurrent oligodendrogliomas (P-values not shown). The 11 cases contributed by UCSF (cases 1750, 1775, 1779, 1892, 1906, 1913, 2051, 2114, 2167, 2186, and 2235) were not included in calculations of alteration incidence, since these cases originated as part of a pilot study to determine the abilities of LOH and CGH to distinguish allelic imbalance as loss or gain. This set of 11 tumors was selected from a considerably larger collection based on previous CGH data. The remaining tumors were not selected based upon previous molecular analysis and thus are more re¯ective of the general population of human gliomas. The 11 UCSF cases were, however, included in calculations of modality concordance and correlation -1p36, -19q13.3) , while the remaining two-thirds appeared more genetically similar to the astrocytic phenotype (Kraus et al., 1995; Maintz et al., 1997) . It must be recognized, however, that the MOA category is dicult to de®ne histologically, that its interpretation diered among reviewers, and in some cases it was de®ned more on lack of agreement by the pathologists than on consensus based upon unambiguous histological criteria. Table 2 summarizes the number of cases, divided by morphological subtype and primary/recurrent status, with loss of the 1p36 and 19q13.3 regions of common allelic deletion. Without distinguishing primary and recurrent specimens, the oligodendroglial phenotype was highly associated with loss of 1p (P50.0001), loss of 19q (P=0.0017), and combined loss of 1p and 19q (P50.0001). Interestingly, while the majority of oligodendrogliomas demonstrated loss of both the 1p36 and 19q13.3 regions, three oligodendrogliomas had loss of the 1p36 region without apparent loss of the 19q13.3 region (cases 89, 587 and 588), and three oligodendrogliomas had loss of the 19q13.3 region without apparent alteration of the 1p36 region (cases 100, 240 and 300). It is possible, however, that alterations below the limits of our detection methods may be present in these tumors.
Deletion of the 19p13.1 ± 13.2 region of overlapping loss was observed in seven of 55 astrocytomas (13%) and in six of 33 oligodendrogliomas (18%), but was not signi®cantly associated with either morphologic phenotype (P=0.49).
Excellent concordance has been demonstrated between FISH and LOH for the p16/MTS1/CDKN2 region in diuse gliomas . One objective of this study was to evaluate the abilities of dierent molecular techniques to identify the genetic alterations of chromosomes 1 and 19 in diuse gliomas. Table 3 shows the concordances and correlations among LOH, FISH, and CGH by chromosome arm. Comparisons involving CGH had particularly low correlation coecients for the 1q and 19p chromosome arms, re¯ective of both the low occurrence of imbalance of these arms and the inability of CGH to detect the majority of these lesions. The relatively low CGH concordances and correlations involving 19q alterations resulted, in part, from using microsatellite markers and FISH probes that map to 19q13.3, a region in human gliomas that often contains deletions below the resolution of CGH. Furthermore, CGH has known artifacts at both 1p and 19q (Kallioniemi et al., 1994; Kim et al., 1995; Mohapatra et al., 1995) .
While limitations of space do not permit discussion of all discordances, some of the discordances do warrant further discussion. The 19q CGH data for astrocytoma 187 (normal) is discordant with the LOH data for the same chromosome arm (-19q) . However, since FISH analysis also did not detect hemizygous loss of 19q, it is possible that this represents loss and reduplication of 19q. Other deletions detected by FISH and/or LOH, such as those on 19q for astrocytomas 113, 126, 162 and 285 were possibly not detected by CGH, because these alterations were not large enough to reach the CGH threshold for detection. Thus, these discordances are attributable to the limited resolution of CGH, rather than true technique discordance.
While there was allelic balance for all informative microsatellite markers analysed by LOH for oligodendrogliomas 100 and 240 and astrocytomas 113, 126 and 162, each of these cases had hemizygous deletion of the 19q13.3 FISH probe that maps between the genetic markers D19S412 and D19S596. Though these cases were treated as discordances based on the design of this study, they do not represent true technique discordances, since further analysis utilizing newly developed microsatellite markers in the region has demonstrated that this region is indeed hemizygously deleted in these tumors by LOH analysis (Smith et al., unpublished data) .
The results of all three molecular techniques appear to be discordant for astrocytoma 168. LOH found hemizygous deletion of 19p and overrepresentation of 19q, while FISH demonstrated two copies of the 19p probe and four copies of each 19q probe and CGH detected no alteration of chromosome 19. The combined results of LOH and FISH suggest that one chromosome 19 had a short arm deletion with subsequent reduplication of the abnormal chromosome. Although this mechanism explains the FISH and LOH results, it is not consistent with the CGH results. However, only 22% of cells had abnormal FISH probe signal numbers, thus the number of abnormal cells may have been below the limit of detection by CGH.
In this study we have demonstrated that FISH and LOH have excellent concordance and correlation for the detection of 1p and 19q alterations in human gliomas and that CGH, while capable of detecting the majority of gross alterations, failed to detect the relatively small deletions that were commonly encountered. In addition, we have demonstrated the spectrum of alterations of chromsomes 1 and 19 in a large set of gliomas and have identi®ed regions of overlapping deletion on 1p, 19p, and 19q as potential sites for tumor suppressor genes. Furthermore, we have examined the association of these regions of common loss with histological subtypes of gliomas and observed that simultaneous loss of the 1p and 19q common deletion regions is associated with the oligodendroglial phenotype. These data should facilitate continued clinical investigation of these alterations and contribute to the ongoing search for the genetic elements underlying their associations with prognosis and chemosensitivity.
